Research Topics
| AARON JACOB MARCUSSummaryAffiliation: Cornell University Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
CD39 activity correlates with stage and inhibits platelet reactivity in chronic lymphocytic leukemiaDianne Pulte
Research Service, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
J Transl Med 5:23. 2007....- Thromboregulation by endothelial cells: significance for occlusive vascular diseasesA Marcus
VA New York Harbor Healthcare System and Weill Medical College of Cornell University, New York, NY 10010, USA
Arterioscler Thromb Vasc Biol 21:178-82. 2001.... - Inhibition of platelet recruitment by endothelial cell CD39/ecto-ADPase: significance for occlusive vascular diseasesA J Marcus
Department of Medicine, VA New York Harbor Healthcare System and Weill Medical College of Cornell University, NY 10010, USA
Ital Heart J 2:824-30. 2001..In this review, we summarize our recent research results with CD39 and solCD39, and discuss our viewpoints on its present and future possibilities as a novel treatment for thrombosis... - Role of CD39 (NTPDase-1) in thromboregulation, cerebroprotection, and cardioprotectionAaron J Marcus
Weill Medical College of Cornell University, 423 East 23rd Street, New York, NY 10010, USA
Semin Thromb Hemost 31:234-46. 2005..Thus, CD39 represents the next generation of cardioprotective and cerebroprotective molecules. This article focuses on our interpretations of recent data and their implications for therapeutics... - Heterologous cell-cell interactions: thromboregulation, cerebroprotection and cardioprotection by CD39 (NTPDase-1)A J Marcus
Department of Medicine, Weill Medical College of Cornell University, and Medical Service Hematology Oncology, VA New York Harbor Healthcare System, New York, NY 10010, USA
J Thromb Haemost 1:2497-509. 2003..This reduction can prevent fatal arrhythmia. Moreover, solCD39 ameliorated the sequelae of stroke in CD39 null mice. CD39 represents the next generation of cardioprotective and cerebroprotective molecules... - Metabolic control of excessive extracellular nucleotide accumulation by CD39/ecto-nucleotidase-1: implications for ischemic vascular diseasesAaron J Marcus
Department of Medicine, Department of Medicine, College of Physicians and Surgeons, Columbia University, New York, New York 10010, USA
J Pharmacol Exp Ther 305:9-16. 2003..quot;Reconstitution" of CD39 null mice with solCD39 reversed these changes. We hypothesize that solCD39 has potential as a novel therapeutic agent for thrombotic diatheses... - The endothelial cell ecto-ADPase responsible for inhibition of platelet function is CD39A J Marcus
Department of Medicine, Veterans Affairs Medical Center, New York 10010 5050, USA
J Clin Invest 99:1351-60. 1997..The identification of HUVEC ADPase/CD39 as a constitutively expressed potent inhibitor of platelet reactivity offers new prospects for antithrombotic therapeusis... - Human solCD39 inhibits injury-induced development of neointimal hyperplasiaJ H F Drosopoulos
Thrombosis Research Laboratory, Room 13026W, VA New York Harbor Healthcare System, 423 East 23rd Street, New York, N Y 10010 5050, USA
Thromb Haemost 103:426-34. 2010..56 +/- 0.34 at 19 days). Thus, systemic administration of solCD39 profoundly affects injury-induced cellular responses, minimising platelet deposition and leukocyte recruitment, and suppressing neointimal hyperplasia... - Site-directed mutagenesis of human endothelial cell ecto-ADPase/soluble CD39: requirement of glutamate 174 and serine 218 for enzyme activity and inhibition of platelet recruitmentJ H Drosopoulos
Department of Medicine, Division of Hematology and Medical Oncology, VA New York Harbor Healthcare System, New York, New York 10010 5050, USA
Biochemistry 39:6936-43. 2000..Thus, glutamate 174 and serine 218 are essential for both the enzymatic and biological activity of solCD39... - Role of extracellular ATP metabolism in regulation of platelet reactivityAlex V Birk
Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
J Lab Clin Med 140:166-75. 2002..The presence of both endothelial CD39 and plasma nucleotidase appears to be important in the maintenance of normal hemostasis and prevention of excessive platelet responsiveness... - Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular diseaseM Teresa Santos
Research Center, Hospital Universitario La Fe, Valencia, Spain
J Lab Clin Med 147:220-7. 2006.... - EctoNucleotidase in cardiac sympathetic nerve endings modulates ATP-mediated feedback of norepinephrine releaseCasilde Sesti
Department of Pharmacology, Weill Medical College of Cornell University, New York, New York 10021, USA
J Pharmacol Exp Ther 300:605-11. 2002..We propose that ectonucleotidase control of norepinephrine release should provide cardiac protection in hyperadrenergic states such as myocardial ischemia... - Role of a novel soluble nucleotide phospho-hydrolase from sheep plasma in inhibition of platelet reactivity: hemostasis, thrombosis, and vascular biologyAlex V Birk
Division of Hematology and Medical Oncology, Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
J Lab Clin Med 139:116-24. 2002.... - Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brainDavid J Pinsky
Division of Cardiology, Department of Medicine, College of Physicians and Surgeons, Columbia University, Presbyterial Hospital 10 Stem, 630 W 168th Street, New York, NY 10032, USA
J Clin Invest 109:1031-40. 2002..solCD39 reconstituted these mice, restoring postischemic cerebral perfusion and rescuing them from cerebral injury. These data demonstrate that CD39 exerts a protective thromboregulatory function in stroke... - Targeted deletion of ectonucleoside triphosphate diphosphohydrolase 1/CD39 leads to desensitization of pre- and postsynaptic purinergic P2 receptorsUlrich Schaefer
Department of Pharmacology, Weill Cornell Medical College, 1300 York Ave, New York, NY, USA
J Pharmacol Exp Ther 322:1269-77. 2007..Moreover, by virtue of its antithrombotic action CD39 can potentially prevent the transition from myocardial ischemia to infarction... - Effects of SolCD39, a novel inhibitor of Platelet Aggregation, on Platelet Deposition and Aggregation after PTCA in a Porcine ModelJohn M Buergler
Section of Cardiology, Department of Medicine, Baylor College of Medicine, The Methodist DeBakey Heart Center, Houston, TX 77030, USA
J Thromb Thrombolysis 19:115-22. 2005..CD39 (E-NTPDase1), is the endothelial ecto-ADPase inhibiting platelet function via hydrolysis of released platelet ADP... - Thrombospondins deployed by thrombopoietic cells determine angiogenic switch and extent of revascularizationHans Georg Kopp
Howard Hughes Medical Institute, Department of Genetic Medicine, Weill Medical College of Cornell University, New York, NY 10021, USA
J Clin Invest 116:3277-91. 2006..As such, interference with the release of cellular stores of TSPs may be clinically effective in augmenting neoangiogenesis... - CD39/NTPDase-1 activity and expression in normal leukocytesE Dianne Pulte
Research Service, Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, United States
Thromb Res 121:309-17. 2007..CD39 is expressed on numerous different types of normal leukocytes, but details of its expression have not been determined previously... - The ratio of ADP- to ATP-ectonucleotidase activity is reduced in patients with coronary artery diseaseMagdi M El-Omar
Department of Medicine-Cardiology, New York University Medical School, New York, NY, USA
Thromb Res 116:199-206. 2005..Increased generation of prothrombotic ADP in these patients implies a potential benefit from therapeutic intervention with soluble forms of CD39... - Ectonucleoside triphosphate diphosphohydrolase 1/CD39, localized in neurons of human and porcine heart, modulates ATP-induced norepinephrine exocytosisTakuji Machida
Department of Pharmacology, Weill Medical College of Cornell University, New York, NY 10021, USA
J Pharmacol Exp Ther 313:570-7. 2005..By curtailing NE release, in addition to its effects as an antithrombotic agent, soluble CD39 may constitute a novel therapeutic approach to ischemic complications in the myocardium... - Cell-type specificity of ectonucleotidase expression and upregulation by 2,3,7,8-tetrachlorodibenzo-p-dioxinEmily Wood
Department of Pharmacology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
Arch Biochem Biophys 407:49-62. 2002..It is likely that such differences are important for cell-specific susceptibility to extracellular nucleotide toxicity and responses to purinergic signaling... - COX inhibitors and thromboregulationAaron J Marcus
Veterans Affairs New York Harbor Healthcare System, New York, NY 10010, USA
N Engl J Med 347:1025-6. 2002 - Ectonucleotidase in sympathetic nerve endings modulates ATP and norepinephrine exocytosis in myocardial ischemiaCasilde Sesti
Department of Pharmacology, Room LC419, 1300 York Ave, Weill Medical College of Cornell University, New York, NY 10021, USA
J Pharmacol Exp Ther 306:238-44. 2003..Because excessive NE release is an established cause of dysfunction in ischemic heart disease, solCD39 may offer a novel therapeutic approach to myocardial ischemia and its consequences...
Research Grants
- CELL-CELL INTERACTIONS IN THROMBOSISAaron Marcus; Fiscal Year: 2003....
- VASCULAR CONTROL OF BLOOD CELL REACTIVITY IN THROMBOSISAaron Marcus; Fiscal Year: 2005..This collaboration, based on compelling feasibility data and historical collaborative success, will advance the understanding of CD39 thromboregulation, and lead to a novel therapeutic agent for thrombotic diathesis. ..
- CELL-CELL INTERACTIONS IN THROMBOSISAaron Marcus; Fiscal Year: 2007..abstract_text> ..
- CELL-CELL INTERACTIONS IN THROMBOSISAaron Marcus; Fiscal Year: 1993..Established experimental methods include: Separate measurement of platelet activation and recruitment, tissue culture, TLC, HPLC, GC/MS, aggregometry and radioimmunoassay...
- CELL/CELL INTERACTIONS IN THROMBOSISAaron Marcus; Fiscal Year: 1999..Experiments proposed in this application will furnish information for future development of rational and effective forms of antithrombotic therapy which will act at the very earliest stages of thrombus formation. ..
- Thromboregulation in Occlusive Vascular DiseasesAARON JACOB MARCUS; Fiscal Year: 2010..We anticipate that the research proposed herein will lead to formulation of a clinical trial of a human soluble apyrase such as solCD39. ..